SAB Biotherapeutics to Go Public via Merger with Big Cypress Acquisition Corp.

OceanTech Acquisitions I Corp and Captura Biopharma Sign Definitive Business Combination Agreement

August 10, 2022

Biotechnology

OceanTech Acquisitions I Corp., a special purpose acquisition company, signed a definitive merger agreement with Captura Biopharma to take the biotech company public. The combined company is expected to operate under the name Captura Biopharma Holdings, Inc. and remain listed on Nasdaq, subject to SEC, regulatory, and stockholder approvals.

Cybin Inc. Acquires Small Pharma Inc.

August 28, 2023

Biotechnology

Cybin Inc. has agreed to acquire all issued and outstanding securities of U.K.-based Small Pharma in an all‑share plan of arrangement. The transaction combines Cybin's and Small Pharma's clinical-stage psychedelic therapeutic programs and IP into a single, publicly traded clinical‑stage biopharmaceutical company headquartered in Toronto.

GlycoMimetics to Acquire Crescent Biopharma (Merger to Operate as Crescent Biopharma, Inc.)

October 29, 2024

Healthcare Services

GlycoMimetics entered into an acquisition agreement with privately held oncology-focused biotechnology company Crescent Biopharma. The combined company will operate under the name Crescent Biopharma, Inc., advancing Crescent’s precision-engineered biologics for solid tumors, including the lead program CR-001, alongside ADC programs CR-002 and CR-003, supported by approximately $200 million in committed financing. GlycoMimetics stockholders approved the proposed merger in June 2025, and the combined company is expected to begin trading on Nasdaq on June 16, 2025 under the new ticker.

Candid Therapeutics to Merge With Rallybio (Creating Nasdaq-listed Candid Therapeutics)

March 5, 2026

Biotechnology

Clinical-stage biotechnology company Candid Therapeutics signed a merger agreement with Rallybio Corporation to create a combined company focused on developing T cell engager therapies for autoimmune diseases. The transaction is expected to close in mid-2026, pending customary approvals and conditions, and Candid also secured an oversubscribed private financing of more than $505 million led by healthcare institutional investors.

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

February 12, 2024

Pharmaceuticals

Gilead Sciences, Inc. agreed to acquire CymaBay Therapeutics, Inc. for an equity value of approximately $4.3 billion, or $32.50 per share in cash. The acquisition adds CymaBay’s investigational lead asset seladelpar for the treatment of primary biliary cholangitis (PBC), complementing Gilead’s existing liver portfolio.

Atlantic Coastal Acquisition Corp. II Completes Business Combination with Abpro Corporation

November 13, 2024

Biotechnology

Abpro Corporation and Atlantic Coastal Acquisition Corp. II completed their business combination and the combined company will operate as Abpro Holdings, Inc., with Abpro Corporation as a wholly owned subsidiary. The company is expected to begin trading on Nasdaq under the ticker ABP (and ABPWW for warrants); South Korea's Celltrion participated in a $5.0 million PIPE and appointed Soo Young Lee to Abpro's board.